这篇文章是美国癌症协会关于美国女性乳腺癌统计数据的最新更新，包括发病率、死亡率、生存率和乳房X线摄影筛查的人口数据。在过去的四十年中，乳腺癌发病率已经上升；在最近的数据年份(2010-2019年)中，发病率每年上升0.5%，主要由局部晚期和激素受体阳性疾病所驱动。相反，乳腺癌死亡率自1989年达到峰值以来逐渐下降，尽管在近年来的速度(从2011年到2020年每年下降1.3%)比上一个十年(从2002年到2011年每年下降1.9%)慢。在1989年至2020年间，死亡率总计下降了43%，在这段时间内少了46万人死于乳腺癌。除了美洲印第安人/阿拉斯加原住民之外，所有族裔/种族女性的死亡率都有所下降，后者的比率保持稳定。然而，尽管黑人女性发病率较白人女性低(每10万人127.8人对133.7人)，但是种族死亡率差距仍然不会改变，在黑人女性整体死亡率方面高40%(2016-2020年每10万人27.6人对19.7人)，在50岁以下的成年女性中高两倍(每10万人12.1人对6.5人)。对于每一种分子亚型和疾病阶段，黑人女性都有着最低的5年相对生存率(除I期外)，在激素受体阳性/人类表皮生长因子受体2阴性疾病(88%对96%)、激素受体阴性/人类表皮生长因子受体阳性疾病(78%对86%)和III期疾病(64%对77%)的绝对差距最大。通过通过全国医疗补助扩展和社区利益相关者、倡导组织和卫生系统之间的合作，增加高质量筛查和治疗的获取率，可以加速减少种族差异，进一步推进乳腺癌死亡率的进展。©2022年作者和Wiley Periodicals LLC代表美国癌症协会发表的CA: 临床肿瘤学杂志。

This article is the American Cancer Society's update on female breast cancer statistics in the United States, including population-based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010-2019), the rate increased by 0.5% annually, largely driven by localized-stage and hormone receptor-positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989-2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016-2020) and two-fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5-year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black-White gaps in absolute terms for hormone receptor-positive/human epidermal growth factor receptor 2-negative disease (88% vs. 96%), hormone receptor-negative/human epidermal growth factor receptor 2-positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high-quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.© 2022 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.